Program
Aprepitant
Also written as “aprepitant”, “MK0869, aprepitant” and “Aprepitant Injection”.
Its studies are mostly in Depressive Disorder, Major · Vomiting · Nausea · Postoperative Nausea and Vomiting · Pruritus, led by 7 companies.
Drug pageAprepitant: every studyMany companies study it; this page follows only the 27 they lead. All 128 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 210 open or running | phase 4since Sep 21, 2004 | May 2, 2002 | none ahead |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 3since Jul 17, 2024 | Jul 17, 2024 | none ahead |
| Lahore Medical Research Center, LLPits history only | 10 open or running | phase 3since Feb 23, 2024 | Feb 23, 2024 | none ahead |
| LEO Pharmaits history only | 10 open or running | phase 2since Sep 18, 2013 | Sep 18, 2013 | none ahead |
| Nuformix Technologies | 10 open or running | phase 1since Mar 20, 2019 | Mar 20, 2019 | none ahead |
| Ono Pharmaceuticalits history only | 10 open or running | phase 2since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 3since Apr 10, 2025 | Apr 10, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Nuformix Technologies only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 20, 2019First study: phase 1 study in HealthyFirst studyNCT03889366 · 12 enrolled · United Kingdom
TargetBeta
“Neurokinin 1 receptor antagonist”ChEMBL 37, by rule
Other programs on TACR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elinzanetantrule | Bayer | phase 3 | 24 |
| tradipitantrule | Vanda Pharmaceuticals | phase 3 | 19 |
| fosnetupitantrule | Helsinn Healthcare | phase 3 | 2 |
| HRS5580 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
The one study Nuformix Technologies leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03889366Healthy · United Kingdom | 1 | Completed | Apr 15, 2019 | 12 |
How it is read
Names in the registry
- “aprepitant”, 8 entries
- “Aprepitant”, 4 entries
- “MK0869, aprepitant”, 4 entries
- “Aprepitant Injection”, 2 entries
- “Aprepitant 125 mg”, 2 entries
Codes read as this program: MK0869.
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 9 studies
- Vomiting, 7 studies
- Nausea, 4 studies
- Postoperative Nausea and Vomiting, 3 studies
- Pruritus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.